Supramolecular Inhibition of Neurodegeneration by a Synthetic Receptor

ACS Medicinal Chemistry Letters

Volumn 6, Issue 12, 2015, Pages 1174-1178

  Li, Shengke ^a   Chen, Huanxian ^a   Yang, Xue ^a   Bardelang, David ^b   Wyman, Ian W ^c   Wan, Jianbo ^a   Lee, Simon M Y ^a   Wang, Ruibing ^a  

^a University of Macau   (Macao)

^b AIX MARSEILLE UNIV   (France)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

cucurbituril; inhibition; Neurodegeneration; neurotoxin; supramolecular complexation

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ARTIFICIAL RECEPTOR; CUCURBIT[7]URIL; NEUROPROTECTIVE AGENT; NEUROTOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DENSITY FUNCTIONAL THEORY; ELECTROSPRAY MASS SPECTROMETRY; ENCAPSULATION; MOLECULAR MODEL; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; ULTRAVIOLET SPECTROSCOPY; ZEBRA FISH;

EID: 84949749524     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00372     Document Type: Article

References (39)

1. Langston, J. W.; Ballard, P.; Tetrud, J. W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis Science 1983, 219, 979-980 10.1126/science.6823561
2. Lin, M. T.; Beal, M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases Nature 2006, 443, 787-795 10.1038/nature05292
3. Duty, S.; Jenner, P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease Br. J. Pharmacol. 2011, 164, 1357-1391 10.1111/j.1476-5381.2011.01426.x
4. Hare, D. J.; Adlard, P. A.; Doble, P. A.; Finkelstein, D. I. Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity Metallomics 2013, 5, 91-109 10.1039/c2mt20164j
5. Del-Bel, E.; Tumas, V. Parkinson's disease: Some current therapies and their limitations Frontiers in Parkinson's Disease Research 2012, 93
6. Lee, J. W.; Samal, S.; Selvapalam, N.; Kim, H.-J.; Kim, K. Cucurbituril Homologues and Derivatives: New Opportunities in Supramolecular Chemistry Acc. Chem. Res. 2003, 36, 621-630 10.1021/ar020254k
7. Lagona, J.; Mukhopadhyay, P.; Chakrabarti, S.; Isaacs, L. The Cucurbit[n]uril Family Angew. Chem., Int. Ed. 2005, 44, 4844-4870 10.1002/anie.200460675
8. Macartney, D. H. Encapsulation of Drug Molecules by Cucurbiturils: Effects on their Chemical Properties in Aqueous Solution Isr. J. Chem. 2011, 51, 600-615 10.1002/ijch.201100040
9. Walker, S.; Oun, R.; McInnes, F. J.; Wheate, N. J. The Potential of Cucurbit[n]urils in Drug Delivery Isr. J. Chem. 2011, 51, 616-624 10.1002/ijch.201100033
10. Ghosh, I.; Nau, W. M. The strategic use of supramolecular pKa shifts to enhance the bioavailability of drugs Adv. Drug Delivery Rev. 2012, 64, 764-783 10.1016/j.addr.2012.01.015
11. Chen, H.; Chan, J. Y. W.; Li, S.; Liu, J. J.; Wyman, I. W.; Lee, S. M. Y.; Macartney, D. H.; Wang, R. In vivo reversal of general anesthesia by cucurbit[7]uril with zebrafish models RSC Adv. 2015, 5, 63745-63752 10.1039/C5RA09406B
12. Li, S.; Miao, X.; Wyman, I. W.; Li, Y.; Zheng, Y.; Wang, Y.; Macartney, D. H.; Wang, R. High-affinity host-guest complex of cucurbit[7]uril with a bis(thiazolium) salt RSC Adv. 2015, 5, 56110-56115 10.1039/C5RA04468E
13. Miao, X.; Li, Y.; Wyman, I.; Lee, S. M. Y.; Macartney, D. H.; Zheng, Y.; Wang, R. Enhanced in vitro and in vivo uptake of a hydrophobic model drug coumarin-6 in the presence of cucurbit[7]uril MedChemComm 2015, 6, 1370-1374 10.1039/C5MD00189G
14. Bardelang, D.; Casano, G.; Poulhes, F.; Karoui, H.; Filippini, J.; Rockenbauer, A.; Rosas, R.; Monnier, V.; Siri, D.; Gaudel-Siri, A.; Ouari, O.; Tordo, P. Spin exchange monitoring of the strong positive homotropic allosteric binding of a tetraradical by a synthetic receptor in water J. Am. Chem. Soc. 2014, 136, 17570-17577 10.1021/ja509586k
15. Wang, R.; Bardelang, D.; Waite, M.; Udachin, K. A.; Leek, D. M.; Yu, K.; Ratcliffe, C. I.; Ripmeester, J. A. Inclusion complexes of coumarin in cucurbiturils Org. Biomol. Chem. 2009, 7, 2435-2439 10.1039/b903057c
16. Wang, R.; Yuan, L.; Macartney, D. H. Inhibition of C(2)-H/D exchange of a bis(imidazolium) dication upon complexation with cucubit[7]uril Chem. Commun. 2006, 2908-2910 10.1039/b605919h
17. Wang, R.; Yuan, L.; Macartney, D. H. A green to blue fluorescence switch of protonated 2-aminoanthracene upon inclusion in cucurbit[7]uril Chem. Commun. 2005, 5867-5869 10.1039/b513246k
18. Chen, H.; Chan, J. Y. W.; Yang, X.; Wyman, I. W.; Bardelang, D.; Macartney, D. H.; Lee, S. M. Y.; Wang, R. Developmental and organ-specific toxicity of cucurbit[7]uril: in vivo study on zebrafish models RSC Adv. 2015, 5, 30067-30074 10.1039/C5RA04335B
19. Ma, D.; Zhang, B.; Hoffmann, U.; Sundrup, M. G.; Eikermann, M.; Isaacs, L. Acyclic cucurbit[n]uril-type molecular containers bind neuromuscular blocking agents in vitro and reverse neuromuscular block in vivo Angew. Chem., Int. Ed. 2012, 51, 11358-11362 10.1002/anie.201206031
20. Oun, R.; Floriano, R. S.; Isaacs, L.; Rowan, E. G.; Wheate, N. J. The neurotoxic, myotoxic and cardiotoxic activity of cucurbituril-based macrocyclic drug delivery vehicles Toxicol. Res. 2014, 3, 447-455 10.1039/C4TX00082J
21. Lee, H. H.; Choi, T. S.; Lee, S. J.; Lee, J. W.; Park, J.; Ko, Y. H.; Kim, W. J.; Kim, K.; Kim, H. I. Supramolecular inhibition of amyloid fibrillation by cucurbit[7]uril Angew. Chem., Int. Ed. 2014, 53, 7461-7465 10.1002/anie.201402496
22. Da Silva, J. P.; Choudhury, R.; Porel, M.; Pischel, U.; Jockusch, S.; Hubbard, P. C.; Ramamurthy, V.; Canario, A. V. Synthetic versus natural receptors: supramolecular control of chemical sensing in fish ACS Chem. Biol. 2014, 9, 1432-1436 10.1021/cb500172u
23. Vial, L.; Ludlow, R. F.; Leclaire, J.; Pérez-Fernández, R.; Otto, S. Controlling the Biological Effects of Spermine Using a Synthetic Receptor J. Am. Chem. Soc. 2006, 128, 10253-10257 10.1021/ja062536b
24. Hirose, K. A practical guide for the determination of binding constants J. Inclusion Phenom. Mol. Recognit. Chem. 2001, 39, 193-209 10.1023/A:1011117412693
25. Moon, K.; Kaifer, A. E. Modes of binding interaction between viologen guests and the cucurbit[7]uril host Org. Lett. 2004, 6, 185-188 10.1021/ol035967x
26. Ong, W.; Gómez-Kaifer, M.; Kaifer, A. E. Cucurbit[7]uril: A Very Effective Host for Viologens and Their Cation Radicals Org. Lett. 2002, 4, 1791-1794 10.1021/ol025869w
27. Ong, W.; Kaifer, A. E. Salt effects on the apparent stability of the cucurbit[7]uril-methyl viologen inclusion complex J. Org. Chem. 2004, 69, 1383-1385 10.1021/jo035030+
28. Kim, H. J.; Jeon, W. S.; Ko, Y. H.; Kim, K. Inclusion of methylviologen in cucurbit[7]uril Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 5007-5011 10.1073/pnas.062656699
29. Houk, K. N.; Leach, A. G.; Kim, S. P.; Zhang, X. Binding affinities of host-guest, protein-ligand, and protein-transition-state complexes Angew. Chem., Int. Ed. 2003, 42, 4872-4897 10.1002/anie.200200565
30. Saleh, N.; Koner, A. L.; Nau, W. M. Activation and stabilization of drugs by supramolecular pKa shifts: drug-delivery applications tailored for cucurbiturils Angew. Chem., Int. Ed. 2008, 47, 5398-5401 10.1002/anie.200801054
31. Babin, P. J.; Goizet, C.; Raldua, D. Zebrafish models of human motor neuron diseases: advantages and limitations Prog. Neurobiol. 2014, 118, 36-58 10.1016/j.pneurobio.2014.03.001
32. Pienaar, I. S.; Gotz, J.; Feany, M. B. Parkinson's disease: insights from non-traditional model organisms Prog. Neurobiol. 2010, 92, 558-571 10.1016/j.pneurobio.2010.09.001
33. Zhu, Y.; Zhang, J.; Zeng, Y. Overview of tyrosine hydroxylase in Parkinson's disease CNS Neurol. Disord.: Drug Targets 2012, 11, 350-358 10.2174/187152712800792901
34. Lam, C. S.; Korzh, V.; Strahle, U. Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP Eur. J. Neurosci. 2005, 21, 1758-1762 10.1111/j.1460-9568.2005.03988.x
35. Sallinen, V.; Torkko, V.; Sundvik, M.; Reenila, I.; Khrustalyov, D.; Kaslin, J.; Panula, P. MPTP and MPP+ target specific aminergic cell populations in larval zebrafish J. Neurochem. 2009, 108, 719-731 10.1111/j.1471-4159.2008.05793.x
36. Cui, W.; Zhang, Z.; Li, W.; Hu, S.; Mak, S.; Zhang, H.; Han, R.; Yuan, S.; Li, S.; Sa, F.; Xu, D.; Lin, Z.; Zuo, Z.; Rong, J.; Ma, E. D.; Choi, T. C.; Lee, S. M.; Han, Y. The anti-cancer agent SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS Br. J. Pharmacol. 2013, 168, 1201-1214 10.1111/bph.12004
37. Smeyne, R. J.; Jackson-Lewis, V. The MPTP model of Parkinson's disease Mol. Brain Res. 2005, 134, 57-66 10.1016/j.molbrainres.2004.09.017
38. Giros, B.; el Mestikawy, S.; Godinot, N.; Zheng, K.; Han, H.; Yang-Feng, T.; Caron, M. G. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter Mol. Pharmacol. 1992, 42, 383-390
39. Kinemuchi, H.; Arai, Y.; Toyoshima, Y. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Relationship between the enzyme inhibition and the neurotoxicity Neurosci. Lett. 1985, 58, 195-200 10.1016/0304-3940(85)90163-6